Baxter International Inc.
BAX
주식 순위
#1651
Baxter International Inc., operating globally via its subsidiaries, is a... Baxter International Inc., operating globally via its subsidiaries, is a leading developer and provider of a wide spectrum of healthcare products. The company's comprehensive portfolio includes various dialysis treatments, such as peritoneal and hemodialysis, along with related therapies and services. It also specializes in intravenous (IV) therapies, infusion pumps, administration sets, and devices for drug reconstitution. Further expanding its pharmaceutical offerings, Baxter delivers pre-mixed and oncology drug platforms, inhaled anesthetic agents, critical care products, and pharmacy compounding services. Nutritional support is provided through its parenteral nutrition therapies and associated products. For surgical procedures, the company develops biological products and medical devices vital for achieving hemostasis, tissue sealing, and preventing adhesions. Additionally, Baxter supplies continuous renal replacement therapies (CRRT) and other organ support solutions, primarily tailored for intensive care units. Beyond direct medical supplies, Baxter provides sophisticated connected care solutions, integrating devices, software, communication systems, and other advanced technologies. This includes a range of patient monitoring and diagnostic technologies designed to aid in the diagnosis, treatment, and management of numerous illnesses and conditions, spanning respiratory therapy, cardiology, vision screening, and physical assessment. The surgical suite benefits from its specialized video technologies, operating tables, lights, pendants, precision positioning tools, and various ancillary accessories. The company also offers contracted services to a multitude of pharmaceutical and biopharmaceutical companies. Baxter's products are utilized across diverse healthcare environments, including hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and for home-based patients under medical supervision. Operating in approximately 100 countries, Baxter distributes its extensive product line through a direct sales force, independent distributors, drug wholesalers, and specialty pharmacies or other alternative site providers. The company also holds a collaborative agreement with Celerity Pharmaceutical, LLC, focused on developing generic injectable pre-mixed medications for acute care and oncolytic molecules. Established in 1931, Baxter International Inc. is headquartered in Deerfield, Illinois.
주가
$25.03
마지막 동기화: 2026-10-19
시가총액
$12.94B
변동 (1일)
-1.03%
변동 (1년)
8.19%
국가
US
거래 Baxter International Inc. (BAX)
카테고리
Healthcare
Baxter International Inc. (BAX)의 수익
Jun 2026 기준 수익 TTM: $-483.00M
Baxter International Inc.의 최신 재무 보고서에 따르면 회사의 현재 수익은 $-483.00M입니다. 2024년에 회사는 $-289.00M의 수익을 올렸으며 이는 2023년의 수익 $242.00M과 감소입니다. 이 페이지에 표시된 수익은 이자 및 세금 공제 전 수익으로, 즉 EBIT입니다.
Baxter International Inc.의 수익 기록 (2000 ~ 2026)
연말 수익
| 연도 | 수익 | 변화 |
|---|---|---|
| 2026 (TTM) | $-483.00M | 1,757.69% |
| 2025 | $-26.00M | -91.00% |
| 2024 | $-289.00M | -219.42% |
| 2023 | $242.00M | -107.45% |
| 2022 | $-3.25B | -319.91% |
| 2021 | $1.48B | 14.32% |
| 2020 | $1.29B | 33.20% |
| 2019 | $970.00M | -40.01% |
| 2018 | $1.62B | 47.00% |
| 2017 | $1.10B | -77.80% |
| 2016 | $4.95B | 1,057.48% |
| 2015 | $428.00M | -12.65% |
| 2014 | $490.00M | 30.67% |
| 2013 | $375.00M | -86.79% |
| 2012 | $2.84B | 1.03% |
| 2011 | $2.81B | 48.62% |
| 2010 | $1.89B | -30.87% |
| 2009 | $2.73B | 11.05% |
| 2008 | $2.46B | 16.46% |
| 2007 | $2.11B | 21.08% |
| 2006 | $1.75B | 20.91% |
| 2005 | $1.44B | 235.81% |
| 2004 | $430.00M | -61.91% |
| 2003 | $1.13B | -18.54% |
| 2002 | $1.39B | 41.57% |
| 2001 | $979.00M | 1.77% |
| 2000 | $962.00M | 0.00% |
유사 기업 또는 경쟁사의 수익
| 회사 | 수익 | 수익 차이 | 국가 |
|---|---|---|---|
| $3.81B | -887.95% |
US
|
|
| $4.11B | -950.69% |
FR
|
|
| - | - |
JP
|
|
| $1.59B | -429.19% |
US
|
|
| - | - |
CH
|
